ISPOR EXPANDS SCIENTIFIC STAFF BY ADDITION OF CHIEF SCIENCE OFFICER

Published Sep 1, 2015
Princeton, NJ, USA - The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is pleased to announce it is recruiting for a Senior Director & Chief Science Officer, a new position reporting to the Chief Executive Officer & Executive Director.  This position offers an exceptional opportunity to contribute to the continued success of an internationally recognized health economics and outcomes research society. ISPOR’s knowledge products and services include conferences, education, journals, publications, guidelines, and tools used by thousands of global health economists and health care decision makers annually. By focusing on member input and construction of the consensus view of the appropriate path for advancing HEOR science, the successful candidate will develop, lead, support, and direct strategic initiatives related to research, scientific, and content priorities to accomplish the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. The successful candidate will bring to ISPOR extensive experience.  “We look forward to hearing from senior level candidates with deep professional experience, well versed in health economics and outcomes research as well as a passion for ISPOR.  We encourage applications from the global community based on the following position description”, said Nancy Berg, ISPOR CEO & Executive Director. Further details on the position and application details are available at:  ISPOR eJobs Employment Center.

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×